NetScientific Shares Rise on Successful Completion of AstraZeneca Covid-19 Antibody Test
16 May 2022 - 6:10PM
Dow Jones News
By Anthony O. Goriainoff
Shares in NetScientific PLC rose Monday after it said it has
successfully completed the evaluation of AstraZeneca PLC's Covid-19
antibody test.
Shares at 0725 GMT were up 13 pence, or 19%, at 82 pence.
The London-listed life sciences, technology, investment and
commercialization company said its subsidiary, ProAxsis, completed
the test's development and validation with "impressive performance
evaluation results."
The company said the assay showed exceptional levels of
sensitivity and specificity of 100% and 99.3%, respectively. Also,
it was able to detect immunoglobulin G antibodies--the most common
type of antibody found in blood--in blood samples from individuals
who had been previously infected or vaccinated, and from
individuals known to be infected by the Alpha, Delta and Omicron
variants of the virus, the company said.
"This highly sensitive and specific test provides a significant
enhancement to the company's commercial offering; further extending
product range and reinforcing the continued international
expansion. This fits well with NetScientific's trans-Atlantic
bridges and global strategic plans," Chairman John Clarkson
said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
May 16, 2022 03:55 ET (07:55 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024